CRON Fundamental Analysis - CRONOS GROUP INC

Fundamental Rating

CRON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.

In the past year CRON had a positive cash flow from operations.

CRON had negative earnings in 4 of the past 5 years.

In the past 5 years CRON reported 4 times negative operating cash flow.

1.2 Ratios

CRON has a Return On Assets of 4.29%. This is amongst the best in the industry. CRON outperforms 87.63% of its industry peers.

The Return On Equity of CRON (4.64%) is better than 84.54% of its industry peers.

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROIC	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 39.68%, CRON belongs to the best of the industry, outperforming 97.94% of the companies in the same industry.

CRON's Profit Margin has declined in the last couple of years.

CRON has a Gross Margin (27.65%) which is in line with its industry peers.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	39.68%
GM	27.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CRON has more shares outstanding

Compared to 5 years ago, CRON has more shares outstanding

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CRON has an Altman-Z score of 6.77. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 6.77, CRON belongs to the best of the industry, outperforming 82.99% of the companies in the same industry.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.77

ROIC/WACCN/A

WACC8.99%

2.3 Liquidity

CRON has a Current Ratio of 27.80. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

CRON's Current ratio of 27.80 is amongst the best of the industry. CRON outperforms 96.39% of its industry peers.

A Quick Ratio of 26.75 indicates that CRON has no problem at all paying its short term obligations.

CRON's Quick ratio of 26.75 is amongst the best of the industry. CRON outperforms 95.88% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	27.8
Quick Ratio	26.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 285.71%, which is quite impressive.

Measured over the past years, CRON shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.78% on average per year.

CRON shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.92%.

CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.

The Revenue is expected to grow by 1.87% on average over the next years.

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 16.08, CRON is valued correctly.

CRON's Price/Earnings ratio is rather cheap when compared to the industry. CRON is cheaper than 86.60% of the companies in the same industry.

CRON's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.46.

With a Price/Forward Earnings ratio of 25.61, CRON can be considered very expensive at the moment.

Compared to the rest of the industry, the Price/Forward Earnings ratio of CRON indicates a somewhat cheap valuation: CRON is cheaper than 71.65% of the companies listed in the same industry.

CRON is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	16.08
Fwd PE	25.61

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CRON's earnings are expected to decrease with -39.52% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

NASDAQ:CRON (7/21/2025, 8:00:00 PM)

After market: 2.05 -0.04 (-1.91%)

2.09

+0.08 (+3.98%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-07 2025-08-07

Inst Owners13.12%

Inst Owner Change-0.05%

Ins Owners6.2%

Ins Owner Change12.24%

Market Cap806.07M

Analysts76

Price Target1.77 (-15.31%)

Short Float %1.42%

Short Ratio1.67

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-7.6%

Min Revenue beat(2)-14.99%

Max Revenue beat(2)-0.21%

Revenue beat(4)2

Avg Revenue beat(4)-0.3%

Min Revenue beat(4)-14.99%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)0.25%

Revenue beat(12)4

Avg Revenue beat(12)-4.65%

Revenue beat(16)7

Avg Revenue beat(16)-2.62%

PT rev (1m)1.68%

PT rev (3m)-30.88%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)-500.6%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)1.67%

Revenue NQ rev (3m)-4.17%

Revenue NY rev (1m)0%

Revenue NY rev (3m)2.63%

Valuation

		Industry Rank	Sector Rank
PE	16.08
Fwd PE	25.61
P/S	6.47
P/FCF	N/A
P/OCF	42.53
P/B	0.76
P/tB	0.81
EV/EBITDA	N/A

EPS(TTM)0.13

EY6.22%

EPS(NY)0.08

Fwd EY3.9%

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)0.05

OCFY2.35%

SpS0.32

BVpS2.76

TBVpS2.57

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	39.68%
GM	27.65%
FCFM	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	253.86%
Cap/Sales	21.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	27.8
Quick Ratio	26.75
Altman-Z	6.77

F-Score6

WACC8.99%

ROIC/WACCN/A

Cap/Depr(3y)70.04%

Cap/Depr(5y)158.35%

Cap/Sales(3y)6.62%

Cap/Sales(5y)22.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

EBIT growth 1Y32.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year98.02%

EBIT Next 3Y27.54%

EBIT Next 5Y9.95%

FCF growth 1Y92.98%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y118.45%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens